Any current/future new fundraising through debt or equity?

No specific mention of any current or planned fundraising through debt or equity in the transcript. The company highlights a debt-free balance sheet with net cash of INR 35 billion, indicating strong liquidity and financial flexibility. Management emphasizes strategic investments funded through existing resources. They are actively evaluating synergistic and knowledge-led growth opportunities but have not indicated any capital raising plans. CAPEX for FY27 is guided around INR 500-600 crore, expected to be funded through internal accruals. Overall, no explicit plans or announcements for new de

Any current/future capex/capital investment/strategic investment?

FY27 capex guidance is broadly INR 500 crore to INR 600 crore, with formal guidance expected post Board approval next quarter. Plans are underway for setting up a pharma intermediate plant in India; further details to be announced soon. Expansion from 2 to 3 multipurpose plants, with the third plant largely targeted for pharma business. Company is actively evaluating various strategic and synergistic investment opportunities aligned with knowledge-led capabilities, both within AgChem and potentially outside it. Focus on building differentiated plays in specialty, electronic chemicals, biologic

Future growth expectations in sales/revenue/volumes?

Sequential volume growth expected beginning Q4 FY26, with recovery momentum building into FY27. FY27 is anticipated to see overall revenue growth as industry conditions stabilize and new product ramp-up progresses. Growth in the contract research and manufacturing (CRDMO) pharma business expected to strengthen as capabilities mature, targeting EBITDA positivity once topline hits INR 400-500 crore. Domestic agrochemical growth projected to return on track from FY27 following subdued demand in FY26 due to high channel inventory and regulatory impacts. New product commercialization is a k

Future growth expectations in earnings/operating earnings/profits/EPS?

Q4 FY26 expected to show sequential volume growth, with initial signs of recovery beginning. FY27 anticipated to see growth momentum building with gradual recovery after industry stabilization. Earnings growth expected to be positive in FY27, supported by new product ramp-up and improving market conditions. EBITDA margin may face short-term pressure due to investments, but strong gross margins (around 50-52%) are targeted sustainably. New product portfolio continues to grow (~10% growth in new products for 9 months FY26), supporting de-risking strategy. Biologicals contributing aroun

Current/ Expected Orderbook/ Pending Orders?

As of the quarter ending December 31, 2025, the order book stands at approximately $1.2 billion. The company regularly shares updates on the order book and this figure was confirmed during the earnings call. No indication of a decline in the order book was mentioned; relationships with large European and American customers continue to add new products and evaluations. The $1.2 billion order book reflects a healthy pipeline supporting the company’s contract manufacturing services (CSM) and other businesses. The company expects growth momentum to build from Q4 FY26 and into FY27 as industry cond

IN US

Sale is live|00:00:00left today

P I Industries LtdQ4 FY27Fertilizers & Agrochemicals

P I Industries Ltd Q4 FY27 Earnings Call Analysis

Revenue, margin, capex, fundraise and order book outlook from management commentary.

Price: ₹2,755P/E: 34.6Market Cap: ₹47.3K CrSector: Fertilizers & Agrochemicals

Management growth scorecard

Revenue

Category 4

Margin

Category 3

Fundraise

N/A

Order

N/A

Capex

Yes

1 of 3 growth signals are positive — mixed outlook.

Full analysis

Revenue guidance

Category 4

→Sequential volume growth expected beginning Q4 FY26, with recovery momentum building into FY27.
→FY27 is anticipated to see overall revenue growth as industry conditions stabilize and new product ramp-up progresses.
→Growth in the contract research and manufacturing (CRDMO) pharma business expected to strengthen as capabilities mature, targeting EBITDA positivity once topline hits INR 400-500 crore.
→Domestic agrochemical growth projected to return on track from FY27 following subdued demand in FY26 due to high channel inventory and regulatory impacts.
→New product commercialization is a key driver; 5 new molecules commercialized in AgChem exports and 4 in domestic agriculture in FY26, with 8-10 new molecules expected to be commercialized soon.
→Positive demand signals and stabilization in global and domestic markets underpin management's confidence for mid to high single-digit growth over FY27.

Margin guidance

Category 3

→Q4 FY26 expected to show sequential volume growth, with initial signs of recovery beginning.
→FY27 anticipated to see growth momentum building with gradual recovery after industry stabilization.
→Earnings growth expected to be positive in FY27, supported by new product ramp-up and improving market conditions.
→EBITDA margin may face short-term pressure due to investments, but strong gross margins (around 50-52%) are targeted sustainably.
→New product portfolio continues to grow (~10% growth in new products for 9 months FY26), supporting de-risking strategy.
→Biologicals contributing around 20% of revenue and expected to drive long-term growth with scalable global franchise.
→Operating profits may be impacted short term by investments, but medium-term outlook remains positive with technology and partnership-driven growth.
→Order book remains strong (~$1.2 billion), supporting sustained revenue and profit growth prospects.

3 more insights locked — sign up free to unlock

Fundraise plans

→No specific mention of any current or planned fundraising through debt or equity in the transcript.
→The company highlights a debt-free balance sheet with net cash of INR 35 billion, indicating strong liquidity and financial flexibility.
→Management emphasizes strategic investments funded through existing resources.
→They are actively evaluating synergistic and knowledge-led growth opportunities but have not indicated any capital raising plans.
→CAPEX for FY27 is guided around INR 500-600 crore, expected to be funded through internal accruals.
→Overall, no explicit plans or announcements for new debt or equity fundraising as of now.

Order book

→As of the quarter ending December 31, 2025, the order book stands at approximately $1.2 billion.
→The company regularly shares updates on the order book and this figure was confirmed during the earnings call.
→No indication of a decline in the order book was mentioned; relationships with large European and American customers continue to add new products and evaluations.
→The $1.2 billion order book reflects a healthy pipeline supporting the company’s contract manufacturing services (CSM) and other businesses.
→The company expects growth momentum to build from Q4 FY26 and into FY27 as industry conditions stabilize and new product commercialization progresses.

Capex plans

Yes

→FY27 capex guidance is broadly INR 500 crore to INR 600 crore, with formal guidance expected post Board approval next quarter.
→Plans are underway for setting up a pharma intermediate plant in India; further details to be announced soon.
→Expansion from 2 to 3 multipurpose plants, with the third plant largely targeted for pharma business.
→Company is actively evaluating various strategic and synergistic investment opportunities aligned with knowledge-led capabilities, both within AgChem and potentially outside it.
→Focus on building differentiated plays in specialty, electronic chemicals, biologicals, and pharma segments.
→Investments are seen as long-term value creation rather than short-term expenses, with expectations of future growth engines in pharma and biologicals.

How does P I Industries Ltd rank vs peers in Fertilizers & Agrochemicals?

Pro feature

1P I Industries Ltd

Rev 4Mar 3

See full Fertilizers & Agrochemicals sector rankings

Want more stocks like P I Industries Ltd?

Build an AI portfolio filtered by sector, market cap, and growth rank. Takes 2 minutes.

Build my portfolio